March 24, 2020

Ms. Varsha Rao  
Chief Executive Officer  
Nurx, Inc.  
548 Market Street, Suite 94061  
San Francisco, CA 94104

Dear Ms. Rao:

The Subcommittee on Economic and Consumer Policy requests information about your company’s at-home coronavirus test kits.

On March 20, 2020, the Food and Drug Administration (FDA) cautioned against using at-home testing kits as their accuracy has yet to be clearly determined.\(^1\) On March 21, 2020, FDA made clear that its Emergency Use Authorization Guidelines bar the use of at-home sample collection, and that it “has not authorized any test that is available for purchase for testing yourself at home for COVID-19.”\(^2\)

Given FDA’s statements on this issue, the Subcommittee requests that you respond to the following questions by March 27, 2020, regarding your company’s at home coronavirus tests:

1. When did your company start offering at-home coronavirus test kits for sale to consumers, and when did you stop?

2. How many at-home coronavirus test kits did your company sell, how much did you charge, and how many consumers returned test kits with their samples?

3. Do you intend to destroy all consumer samples received, and if so, when and how will you do so?

---


4. Do you intend to refund all consumers all amounts they paid for at-home coronavirus test kits, and if so, when and how will you do so?

5. How many nasopharyngeal swabs does your company possess, and will you donate them for use with FDA-approved coronavirus tests?

The Committee on Oversight and Reform is the principal oversight committee of the House of Representatives and has broad authority to investigate “any matter” at “any time” under House Rule X. If you have any questions regarding this request, please contact Subcommittee staff at (202) 225-5051.

Sincerely,

Raja Krishnamoorthi  
Chairman  
Subcommittee on Economic and Consumer Policy

Katie Porter  
Member of Congress

cc: The Honorable Michael Cloud, Ranking Member